News - Respiratory and Pulmonary, Pharmaceutical

Filter

Popular Filters

1 to 25 of 301 results

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

30-06-2014

US pharma giant GlaxoSmithKline and US partner Theravance have submitted a supplemental New Drug Application…

Breo ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUSA

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

Stallergenes publishes review of grass pollen tablet confirming efficacy

Stallergenes publishes review of grass pollen tablet confirming efficacy

24-06-2014

French allergen specialist Stallergenes has released comprehensive new data on the 5-grass pollen immunotherapy…

FrancePharmaceuticalResearchRespiratory and PulmonaryStallergenes

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

Verona Pharma to drop VRP700 development after Phase IIa trial fails to meet endpoint

23-06-2014

UK-based biotechnology company Verona Pharma says that the Phase IIa clinical trial to evaluate the efficacy…

PharmaceuticalResearchRespiratory and PulmonaryUKVerona Pharma

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

ALK’s Japanese partner posts mixed results for house dust mite SLIT-tablet

16-06-2014

Denmark-based allergy specialist ALK Abello partner for Japan, Torii Pharmaceutical, has completed its…

ALK AbelloJapanPharmaceuticalRegulationResearchRespiratory and PulmonarySLIT-tabletTorii Pharma

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

AstraZeneca inks up to $232 million deal for Synairgen’s SNG001

12-06-2014

Anglo-Swedish pharma major AstraZeneca has signed a global licence accord with Synairgen, an AIM-listed…

AstraZenecaChronic lower respiratory diseasesHealth Medical PharmaLicensingMajorMedicinePharmaceuticalPulmonologyRespiratory and PulmonarySNG001Synairgen

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

EAACI 2014: ALK presents positive Ph III data on house dust mite SLIT-tablet

10-06-2014

Danish allergy specialist ALK-Abello has presented positive key trial results on its new sublingual allergy…

Alk-AbelloPharmaceuticalResearchRespiratory and PulmonarySLIT-tablet

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

Vectura sees hefty rise in full-year 2013/14 revenues, as loss narrows

21-05-2014

Shares of UK developer of inhaled therapies Vectura gained 3.1% to 131.45 pence in early trading this…

FinancialPharmaceuticalRespiratory and PulmonaryVectura

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

20-05-2014

UK pharma major GlaxoSmithKline has released data showing the safety and efficacy of the addition of…

AdvairGlaxoSmithKlineHealth Medical PharmaHealth Medical PharmaIncruse ElliptaMedicinePharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapyUK

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Ario Pharma strengthens scientific advisory board with two key appointments

Ario Pharma strengthens scientific advisory board with two key appointments

12-05-2014

UK-based biopharmaceutical company Ario Pharma has announced the appointment of Professor Peter Barnes…

BiotechnologyBoardroomPharmaceuticalRespiratory and PulmonaryUK

High medicine cost and low patient compliance are key issues in asthma treatment globally

09-05-2014

World Asthma Day (May 6) saw an uproar in UK media attention due to the National Review of Asthma Deaths…

EuropeHealthcarePharmaceuticalPricingRespiratory and PulmonaryUK

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

09-05-2014

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline and partner…

Anoro ElliptaEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

06-05-2014

USA-based allergy immunotherapy products and services specialist Greer Laboratories today announced the…

Ares Life SciencesGREER LaboratoriesMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenesUSA

US FDA approves GSK’s Incruse Ellipta for COPD

US FDA approves GSK’s Incruse Ellipta for COPD

01-05-2014

The US Food and Drug Administration has approved UK pharma major GlaxoSmithKline’s Incruse (umeclidinium)…

Chronic lower respiratory diseasesCOPDGlaxoSmithKlineIncruseIncruse ElliptaMajorMedicinePharmaceuticalPulmonologyRegulationRespiratory and PulmonaryUKUSA

1 to 25 of 301 results

Back to top